Dr. Lun Kelvin Tsou, associate Investigator of IBPR. Dr, Tsou with his team members had development a noval small molecule drug conjugate, DBPR115, that could
Taivex corporate with Institute of Biotechnology and Pharmaceutical Research (IBPR) at National Health Research Institute, developing a first-in-class small molecule drug, T-1201. This drug had
Taivex corporate with Development Center for Biotechnology (DCB), developed a first-in-class small molecule drug, T-1101. T-1101 is novel oral powder dosage Hec1/Nek2 inhibitor, which block
